Literature DB >> 32128690

Changes in Prostate Cancer Presentation Following the 2012 USPSTF Screening Statement: Observational Study in a Multispecialty Group Practice.

Michael J Barry1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32128690      PMCID： PMC7210319          DOI： 10.1007/s11606-020-05757-7

Source DB:  PubMed          Journal:  J Gen Intern Med        ISSN： 0884-8734            Impact factor:   5.128


× No keyword cloud information.
  7 in total

1.  Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement.

Authors:  Virginia A Moyer
Journal:  Ann Intern Med       Date:  2012-07-17       Impact factor: 25.391

2.  Causes of death in elderly prostate cancer patients and in a comparison nonprostate cancer cohort.

Authors:  C J Newschaffer; K Otani; M K McDonald; L T Penberthy
Journal:  J Natl Cancer Inst       Date:  2000-04-19       Impact factor: 13.506

3.  Screening for prostate cancer decreases the risk of developing metastatic disease: findings from the European Randomized Study of Screening for Prostate Cancer (ERSPC).

Authors:  Fritz H Schröder; Jonas Hugosson; Sigrid Carlsson; Teuvo Tammela; Liisa Määttänen; Anssi Auvinen; Maciej Kwiatkowski; Franz Recker; Monique J Roobol
Journal:  Eur Urol       Date:  2012-06-07       Impact factor: 20.096

4.  A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer.

Authors:  Jonas Hugosson; Monique J Roobol; Marianne Månsson; Teuvo L J Tammela; Marco Zappa; Vera Nelen; Maciej Kwiatkowski; Marcos Lujan; Sigrid V Carlsson; Kirsi M Talala; Hans Lilja; Louis J Denis; Franz Recker; Alvaro Paez; Donella Puliti; Arnauld Villers; Xavier Rebillard; Tuomas P Kilpeläinen; Ulf H Stenman; Rebecka Arnsrud Godtman; Karin Stinesen Kollberg; Sue M Moss; Paula Kujala; Kimmo Taari; Andreas Huber; Theodorus van der Kwast; Eveline A Heijnsdijk; Chris Bangma; Harry J De Koning; Fritz H Schröder; Anssi Auvinen
Journal:  Eur Urol       Date:  2019-02-26       Impact factor: 20.096

5.  Prostate-cancer mortality at 11 years of follow-up.

Authors:  Fritz H Schröder; Jonas Hugosson; Monique J Roobol; Teuvo L J Tammela; Stefano Ciatto; Vera Nelen; Maciej Kwiatkowski; Marcos Lujan; Hans Lilja; Marco Zappa; Louis J Denis; Franz Recker; Alvaro Páez; Liisa Määttänen; Chris H Bangma; Gunnar Aus; Sigrid Carlsson; Arnauld Villers; Xavier Rebillard; Theodorus van der Kwast; Paula M Kujala; Bert G Blijenberg; Ulf-Hakan Stenman; Andreas Huber; Kimmo Taari; Matti Hakama; Sue M Moss; Harry J de Koning; Anssi Auvinen
Journal:  N Engl J Med       Date:  2012-03-15       Impact factor: 91.245

6.  Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up.

Authors:  Fritz H Schröder; Jonas Hugosson; Monique J Roobol; Teuvo L J Tammela; Marco Zappa; Vera Nelen; Maciej Kwiatkowski; Marcos Lujan; Liisa Määttänen; Hans Lilja; Louis J Denis; Franz Recker; Alvaro Paez; Chris H Bangma; Sigrid Carlsson; Donella Puliti; Arnauld Villers; Xavier Rebillard; Matti Hakama; Ulf-Hakan Stenman; Paula Kujala; Kimmo Taari; Gunnar Aus; Andreas Huber; Theo H van der Kwast; Ron H N van Schaik; Harry J de Koning; Sue M Moss; Anssi Auvinen
Journal:  Lancet       Date:  2014-08-06       Impact factor: 79.321

7.  Changes in Prostate Cancer Presentation Following the 2012 USPSTF Screening Statement: Observational Study in a Multispecialty Group Practice.

Authors:  Joseph Presti; Stacey Alexeeff; Brandon Horton; Stephanie Prausnitz; Andrew L Avins
Journal:  J Gen Intern Med       Date:  2019-12-09       Impact factor: 5.128
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.